See more : AfriTin Mining Limited (ATM.L) Income Statement Analysis – Financial Results
Complete financial analysis of Krystal Biotech, Inc. (KRYS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Krystal Biotech, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Kitagawa Seiki Co.,Ltd. (6327.T) Income Statement Analysis – Financial Results
- E.S. Australia Israel Holdings Ltd (AUIS.TA) Income Statement Analysis – Financial Results
- Hawkwing plc (HNG.L) Income Statement Analysis – Financial Results
- Sysco Corporation (0LC6.L) Income Statement Analysis – Financial Results
- ANSYS, Inc. (0HG3.L) Income Statement Analysis – Financial Results
Krystal Biotech, Inc. (KRYS)
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 50.70M | 0.00 | 0.00 | 0.00 | 0.00 | 1.03M | 0.00 | 0.00 |
| Cost of Revenue | 3.09M | 4.05M | 2.77M | 1.85M | 974.00K | 141.00K | 23.00K | 2.00K |
| Gross Profit | 47.61M | -4.05M | -2.77M | -1.85M | -974.00K | 886.00K | -23.00K | -2.00K |
| Gross Profit Ratio | 93.90% | 0.00% | 0.00% | 0.00% | 0.00% | 86.27% | 0.00% | 0.00% |
| Research & Development | 46.43M | 42.46M | 27.88M | 17.94M | 15.62M | 7.76M | 3.21M | 741.00K |
| General & Administrative | 0.00 | 77.74M | 40.39M | 15.06M | 6.47M | 4.16M | 1.56M | 402.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 98.40M | 77.74M | 40.39M | 15.06M | 6.47M | 4.16M | 1.56M | 402.00K |
| Other Expenses | 12.50M | 25.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 157.33M | 120.20M | 68.28M | 33.00M | 22.08M | 11.92M | 4.77M | 1.14M |
| Cost & Expenses | 147.93M | 120.20M | 68.28M | 33.00M | 22.08M | 11.92M | 4.77M | 1.14M |
| Interest Income | 22.62M | 5.22M | 197.00K | 832.00K | 2.99M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 5.22M | 1.49M | 0.00 | 0.00 | 1.03M | 3.15M | 7.00K |
| Depreciation & Amortization | 5.01M | 4.05M | 2.77M | 1.85M | 974.00K | 141.00K | 23.00K | 2.00K |
| EBITDA | 17.90M | -145.20M | -65.31M | -30.32M | -18.11M | -10.75M | -4.63M | -1.14M |
| EBITDA Ratio | 35.31% | 0.00% | 0.00% | 0.00% | 0.00% | -1,146.54% | 0.00% | 0.00% |
| Operating Income | -109.73M | -145.20M | -68.28M | -33.00M | -22.08M | -11.92M | -4.77M | -1.14M |
| Operating Income Ratio | -216.43% | 0.00% | 0.00% | 0.00% | 0.00% | -1,160.27% | 0.00% | 0.00% |
| Total Other Income/Expenses | 122.62M | 5.22M | -1.30M | 832.00K | 2.99M | 1.03M | -3.15M | -7.00K |
| Income Before Tax | 12.90M | -139.98M | -69.57M | -32.17M | -19.09M | -10.89M | -7.92M | -1.15M |
| Income Before Tax Ratio | 25.44% | 0.00% | 0.00% | 0.00% | 0.00% | -1,060.27% | 0.00% | 0.00% |
| Income Tax Expense | 1.97M | 34.05M | 2.73M | 1.64M | 576.14K | -20.14K | 0.00 | 0.00 |
| Net Income | 10.93M | -139.98M | -69.57M | -32.17M | -19.09M | -10.89M | -7.92M | -1.15M |
| Net Income Ratio | 21.56% | 0.00% | 0.00% | 0.00% | 0.00% | -1,060.27% | 0.00% | 0.00% |
| EPS | 0.40 | -5.49 | -3.13 | -1.71 | -1.20 | -0.97 | -1.48 | -0.27 |
| EPS Diluted | 0.39 | -5.49 | -3.13 | -1.71 | -1.20 | -0.97 | -1.48 | -0.27 |
| Weighted Avg Shares Out | 27.15M | 25.49M | 22.20M | 18.79M | 15.90M | 11.20M | 5.36M | 4.28M |
| Weighted Avg Shares Out (Dil) | 27.75M | 25.49M | 22.20M | 18.79M | 15.90M | 11.20M | 5.36M | 4.28M |
Why Krystal Biotech (KRYS) Might Surprise This Earnings Season
Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024
Down -7.21% in 4 Weeks, Here's Why Krystal Biotech (KRYS) Looks Ripe for a Turnaround
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung
Krystal Biotech (KRYS) is on the Move, Here's Why the Trend Could be Sustainable
Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting
Recent Price Trend in Krystal Biotech (KRYS) is Your Friend, Here's Why
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
Source: https://incomestatements.info
Category: Stock Reports